EANS-News: Intercell AG / Intercell's partner Biological E. Ltd. launches Japanese Encephalitis vaccine JEEV® in India

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information

Wien (euro adhoc) - << Novel vaccine to protect children and adults
from Japanese Encephalitis (JE), manufactured by partner Biological
E. Ltd. is now available in India

<< Important milestone towards introduction of vaccine based on
Intercell's modern, cell culture-derived technology in endemic
countries

Vienna (Austria)/ Hyderabad (India), September 13, 2012 - Intercell
AG (VSE: ICLL) today announced that its partner Biological E. Ltd.
launched the product JEEV® - a vaccine to protect children and adults
from Japanese Encephalitis (JE) - in India. The vaccine, manufactured
by Biological E. Ltd. at its facility in Hyderabad and based on
Intercell's technology was approved by the Drugs Controller General
of India (DCGI).

"With the market launch in India we have taken a major step forward
in achieving our goal of rolling-out this Japanese Encephalitis
vaccine in endemic countries with a high medical need in order to
protect children and adults against this terrible disease. Our
strategic partnership with Biological E. has made this possible. Now,
we will continue to fight against this disease and collaborate on
increasing market penetration in the endemic region", states Thomas
Lingelbach, Chief Executive Officer of Intercell AG.

Japanese Encephalitis is endemic in Asia and Southeast Asia, a region
with more than 3 billion inhabitants. In 2005, an epidemic outbreak
of Japanese Encephalitis in Uttar Pradesh, India, and Nepal killed
more than 1,200 children.

Biological E. plans to focus its sales efforts of JEEV® initially on
private market customers including pediatricians and general
practitioners. To ensure a successful product launch, Biological E.
has recruited and trained its own sales force, which will initially
be fully dedicated to the product. According to the product label,
the initial approval age groups of the vaccine are children (>=1 - <3
years of age) and adults (>=18 - <=49 years of age). First deliveries
of JEEV® are planned between mid-September and beginning of October,
with full scale commercial manufacturing commencing shortly
thereafter.

Dr. Vijay Kumar Datla, Chairman & Managing Director of Biological E.
said: "With the launch of JEEV®, the indigenous vaccine with
excellent safety profile and proven efficacy in Indian subjects is
now available to doctors for prevention of Japanese Encephalitis in
children and adults."

Biological E. has submitted the Product Summary File under the WHO
Prequalification process and the same is under review.

The vaccine's further regulatory approval route for other Asian
territories is expected through the World Health Organization -
Novartis will be responsible for the marketing and distribution in
these countries. Following the approval and launch of Intercell's
vaccine against Japanese Encephalitis for adult travelers and
military personnel in Europe, the United States, Canada, Hong Kong,
Singapore, Israel (IXIARO®) and Australia (JESPECT®) the development
of a vaccine to protect children and adults in endemic areas from
Japanese Encephalitis has been a major goal of the Company.

In 2005, Intercell and Biological E. signed a contract for the
development, manufacturing, marketing and distribution in India and
the Indian subcontinent of Intercell's Japanese Encephalitis vaccine.

Further inquiry note:
Intercell AG
Nina Waibel
Corporate Communications
Tel. +43 1 20620-1222
communications@intercell.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: Intercell AG
Campus Vienna Biocenter 3
A-1030 Wien
phone: +43 1 20620-0
FAX: +43 1 20620-800
mail: investors@intercell.com
WWW: www.intercell.com
sector: Biotechnology
ISIN: AT0000612601
indexes: ATX Prime
stockmarkets: official market: Wien
language: English